For instance, PGRMC1 expression increases while cognate, nuclear PR decreases in advanced stages of ovarian cancer, and overexpression of PGRMC1 interferes with the lethality of cisplatin, suggesting a survival role for PGRMC1 in ovarian cancer development [58]. This evidence concerns the gene PGRMC1 and ovarian carcinoma.